go-v.orgcodex
Menu
Page tools

codex · Chemistry

Aptiganel

Diagram for Aptiganel
Aptiganel (Cerestat; CNS-1102) is an unsuccessful drug candidate which acts as a noncompetitive NMDA antagonist, and that was under development by Cambridge Neuroscience, Inc as a treatment for stroke due to its neuroprotective effects. However, despite positive results in animal studies, human tria · image: Wikimedia Commons

Aptiganel (Cerestat; CNS-1102) is an unsuccessful drug candidate which acts as a noncompetitive NMDA antagonist, and that was under development by Cambridge Neuroscience, Inc as a treatment for stroke due to its neuroprotective effects. However, despite positive results in animal studies, human trials showed limited efficacy and undesirable side effects such as sedation and hallucinations, leading to the discontinuation of clinical development.

== Chemistry ==

=== Synthesis ===

1-Naphthylamine is reacted with cyanogen bromide to give 2. Treatment of this intermediate with 3-ethyl-N-methylaniline leads to addition to the cyano group and formation of the corresponding diaryl guanidine, aptiganel, 3.

== History == The drug's failure led to the collapse of Cambridge Neuroscience in 1998 and its eventual sale to CeNeS Pharmaceuticals in 2000.

== See also == Ditolylguanidine CNS-1237 (shares most of the same structural entities) CNS-5161

== References ==

Wikipedia contributors, "Aptiganel", Wikipedia, revision 1375814656, retrieved 21 November 2026, source, CC BY-SA 4.0.

More Chemistry · Search the codex